Application of vancomycin in patients with varying renal function, especially those with augmented renal clearance. (1st December 2016)

• Record Type: Journal Article
• Authors: Chu, Yang; Luo, Yifan; Qu, Lianyue; Zhao, Chunyang; Jiang, Mingyan
• Is Part Of: Pharmaceutical biology. Volume 54:Number 12(2016:Dec.)
• Page Start: 2802
• Page End: 2806
• Publication Date: 2016-12-01
• Subjects: ARC -- creatinine clearance -- dosage regimen -- steady-state trough concentration -- therapeutic drug monitoring; Pharmacognosy -- Periodicals; Materia medica, Vegetable -- Periodicals; 615.321
• DOI: 10.1080/13880209.2016.1183684
• Languages: English
• ISSNs: 1388-0209

Abstract

Abstract: Context: Augmented renal clearance (ARC) refers to enhanced renal elimination of circulating solute, and has attracted wide attention in recent years. Objective: This study evaluates the effects of ARC on serum vancomycin concentration in patients administered vancomycin. Materials and methods: This was a retrospective study in patients receiving vancomycin treatment at a dose of 1000 mg in every 12 h and undergoing serum monitoring admitted over a 2-year period (May 2013 to May 2015), in order to estimate the influence of ARC on serum vancomycin concentration. In this study, statistical comparisons were made on the results from patients grouped according to creatinine clearance (CLcr ). Results: One hundred forty-eight patients were enrolled in our study. The results showed that ARC patients were significantly younger, with a significantly lower Scr and higher GFR. The CLcr and steady-state trough concentrations of serum vancomycin exhibited a logarithmic correlation ( Rs = −0.699, R 2 = 0.488, p < 0.01) in the patients included in our study. The trough vancomycin concentrations of 62.9% patients in high CLcr group were under 10 μg/mL. Discussion and conclusion: Since ARC was significantly associated with subtherapeutic serum vancomycin concentration, it was necessary to devise adjusted dosage regimens for these patients based on their CLcr .